AIDS: Therapeutic vaccine "in four or five years" says Montagnier in EP
Last year French Professor Luc Montagnier jointly won the Nobel Prize for Medicine with Françoise Barré-Sinoussi for their discovery of the HIV virus in 1983. On 1 April he took part in a conference on biomedical research organised by the European Parliament. In an exclusive interview we spoke to him about his hopes for a therapeutic vaccine for AIDS sufferers within "four or five years". He also spoke of his worries about a lack of interest in scientific research by young people.
(Click here to continue...)
April 17, 2009
Genetic Immunity's approach appeared in Datamonitor Report.
A large report on vaccine delivery technologies, in which Genetic Immunity’s approach is also introduced appeared in Datamonitor Report in April 2009.
(Click here to see the reference.)
Healthcare division of Datamonitor is an international premium business information and analysis firm based in London. They produce analysis for pharmaceutical and biotech companies as well as other stakeholders on all areas of the healthcare industry, providing data, commentary and market insight. They are an independent and unbiased information provider and not commissioned for their research projects by any particular company.
Febuary 21, 2009
GI in the "Delta" - weekly Hungarian scientific document series.
Documentary on Genetic Immunity's research, development and clinical program.
January 2009: GI in the Italian magazine Capital: a monthly magazine for businessmen
"She left competitive sport and devoted to genetics. In a short time, she founded a model company specialized in the research on serious diseases starting from scratch. And now Julianna Lisziewicz, President of Genetic Immunity, explains that future is the nanomedicine." (Click here to download the full article...)
January 18, 2009
Biopharmaceutical Innovation Potential: What can be done to accelerate AIDS vaccine research and development?
Europe's significant scientific capacity could prove pivotal in the quest for an AIDS vaccine. However, key challenges, including a translational research gap, must be addressed to best harness Europe's expertise. Download full article
December 06, 2008
Reuters - Nobel winner sees end to AIDS spread within years
STOCKHOLM (Reuters) - A French scientist who shared this year's Nobel prize for medicine said on Saturday he believed the transmission of AIDS could be eliminated within years... full article of Reuters
December 06, 2008
GI in DELTA the Hungarian Scientific Documentary Series
In this program there is a report with Julianna Lisziewicz, CEO of Genetic Immunity about HIV as one of the Scientific Nobel Price winner discoveries in 2008.
Dr Julianna Lisziewicz, president of Genetic Immunity gave a Plenary Lecture at the 2nd Europe INNOVA Conference
Dr Julianna Lisziewicz, president of Genetic Immunity gave a Plenary Lecture at the 2nd Europe INNOVA Conference is organized by the French Presidency of the European Union in close collaboration with the European Commission (DG Enterprise & Industry) and hosted by the city of Lyon. The conference addressed policy priorities for accelerating innovation in Europe with particular focus on the role of research-driven innovation and knowledge transfer, the role of strategic partnerships in strengthening industry's innovation capacity and the mechanisms for supporting innovative SMEs and entrepreneurs. Go to homepage of INNOVA Conference... or Download the presentation (in PDF format)
July 13, 2008
Genetic Immunity to Present at 2008 BIO International Convention
The Forbes and other important media reported about Genetic Immunity to present at 2008 BIO International Convention. See the articles below: Forbes (06.13.08) - 2008 BIO International Convention Exhibitor Profiles, Forbes (06.12.08), Reuters (06.12.08).
April 21, 2008
Full viral suppression newest trend seen in the "post-HAART" era
New immunotherapy treatment could help with trend. In what might be called the post-HAART era, there is an encouraging new trend of clinicans seein greater numbers of patients who have undetectable viral lodas, according to an HIV clinican who has been in the trenches for over two decades. (Continued here...)
April 18, 2008
GI Published Data Related to the DermaVir NanomMedicine Patch in the Journal of Immunology
Genetic Immunity Published Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology: Data Supports Use of HIV-specific T cell Precursors with High Proliferative Capacity (PHPC) Marker to Predict Reduction of Viral Load. Blood cells from 32 participants were evaluated via a novel PHPC assay as well as a ELISPOT assay to determine which responses correlate with viral suppression and positive immunologic outcomes. The study indicated that a high magnitude of HIV-specific T cell Precursors with High Proliferative Capacity (PHPC), rather than ELISPOT responses, significantly correlated with low plasma viral loads and is therefore an effective diagnostic measurement for determining which responses correlate with viral suppression and positive immunologic outcomes. In contrast to PHPC, which identifies precursor T-cells with high proliferative capacity, ELISPOT is commonly used to monitor immune responses in humans and animals by identifying effector T-cells with low proliferative capacity.
January 24 2008 Genetic Immunity inaugurated its new office and laboratory facility located in Budapest Berlini street... Dr. Lisziewicz the CEO of Genetic Immunity noted the journey of the project during the past 10 years ?from the Berlin Patient to the Berlin street?. Genetic Immunity has developing immune therapies inspired by an exceptional clinical observation of the Berlin Patient (Lisziewicz at al. New England Journal of Medicine 1999). The facility is the new home for chemistry, biology and molecular biology laboratories required for research and immune therapy product development. DermaVir Patch quality assurance and control studies will also be performed here in the qualified laboratories and product will be released worldwide to clinical trials. Product and clinical development process is supported by an experienced bio-Information Technology (bio-IT) team, a structure what is unique in this emerging biopharmaceutical industry. The office facility is the center for the Company?s executive management team as well as the international clinical development team.
January 22, 2008
GI on BioData Forum in Geneva
Zsolt Lisziewicz, Chief Operating Officer of Genetic Immunity is invited as speaker to the BioData Forum in Geneva (Visit website: www.biodataforum.com)
October 11, 2007
GI in the BioWorld Today
BioWorld Today: "Genetic Immunity LLC, of New York, has completed a $2 million bridge financing. Terms of the financing were not disclosed. The funds will be used to launch an additional Phase II proof-of-concept trial for the DermaVir Patch, the company's product for reconstituting the viral load in HIV-positive people."
Quality scientific publications in Dermatology Open Journals (Bentham Scientific Publishers) See in details...
June 25, 2007
The European Commission has published the second FP7 call for proposals. Identifier: FP7-HEALTH-2007-B Publication date: 19 June 2007 Deadline: 18 September 2007 at 17:00:00 (Brussels local time) OJ Reference:OJ C135 of 19 June 2007 Additional information on the Health research call can be found under cordis.europa.eu
1st International Symposium on Genetic and Immune Correlates of HIV Infection and Vaccine-Induced Immunity 10-13 June, 2007. Budapest, Hungary. VTC (J. Lisziewicz) and Semmelweis University (G. Füst) are coorganizing the conference. For more information visit page www.diamond-congress.hu/hiv2007
Recommendation of the Parliamentary Assembly of the Council of Europe: "...address the development and testing of medicines specifically for use in children living with HIV, and new technologies such as microbicides and HIV/AIDS vaccines" (click here...)
November 22, 2006
Intensive workshop on the project and on future progress of the atherosclerosis group (Programme)
November 10, 2006
On invitation of Prof. Julianna Lisziewicz Dr. Arya Suresh from USA visited us and held a successful seminar (Source)
Dr. Julianna Lisziewicz, Chair of the Vaccine Therapy Cluster is invited as speaker to the AIDS Vaccine 2006 Conference which will take place on August 29 - September 1, 2006 in Amsterdam, The Netherlands. Her presentation title is "DermaVir patch therapeutic vaccine in chronic HIV infection: from the concept to the clinic". And the reaction:
June 12, 2006
Dr. Zsolt Lisziewicz, CEO of Genetic Immunity Kft. is invited to the Life Sciences Partnering China & Europe Programme which will take place on Sept. 18-19 in Beijing, China. Meetings with chinese vaccine development companies and leading CDC (Center of Desease Control) officers are planned as well.
June 12, 2006
Eszter Berzsenyi of Genetic Immunity starts one week visit to RIGHT Italy. She will work under the supervision of Prof. Franco Lori. The goal of her trip is to learn the biological assays characterizing the DermaVir Patch product and transfer these assays to the new Budapest laboratories of Genetic Immunity.
May 30, 2006
Prof. Julianna Lisziewicz, the leader of the Vaccine Therapy Cluster, has visited IATEC in Amsterdam to establish collaboration.
May 26, 2006
Prof. Julianna Lisziewicz, the leader of the Vaccine Therapy Cluster, has visited RIGHT to oversee the collaborative research progress between Genetic Immunity and RIGHT.
May 24, 2006
Prof. Julianna Lisziewicz, the leader of the Vaccine Therapy Cluster, has visited Karolinska Institute in Stockholm to establish collaboration.
May 17, 2006
The Second Management Committee Meeting took place in the Chemical Research Center, Budapest. There was discussion about the scientific progress, the patent and process development issues, ISO operating procedures. CRC team leaders presented excellent progress in vaccine chemistry. Leaders of VTC with Solvo defined the short, medium and long-term business development focus.
May 02, 2006
Dr. Eszter Ujhelyi of St Laszlo Hospital starts one week visit to RIGHT Italy. She will work under the supervision of Prof Franco Lori and Dr. Sandra Calarotta. The goal of her visit is to learn the ELISPOT and Cultured-ELISPOT assay and establish these assays in the clinical immune diagnostic laboratory of Laszlo Hospital.